Related Experiment Videos
Intraperitoneal chemotherapy for stage III ovarian cancer
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Getting to the End Zone With Medicare for All.
The Journal of ambulatory care management·2019
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
The Patient Who Could Not Die.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma.
Korean journal of radiology·2026
Cemiplimab in cutaneous squamous cell carcinoma: a longer follow-up study focusing on the late toxicities.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Not all anti-CD38 antibodies are created equal: The epitope of felzartamab is partially DTT-resistant.
Transfusion medicine (Oxford, England)·2026